Aclarion Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Aclarion şirketinin toplam hissedar öz sermayesi $1.6M ve toplam borcu $777.1K olup, bu da borç-öz sermaye oranını 47.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $3.1M ve $1.4M dir.

Anahtar bilgiler

47.3%

Borç/özkaynak oranı

US$777.09k

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.22m
Eşitlik	US$1.64m
Toplam yükümlülükler	US$1.45m
Toplam varlıklar	US$3.09m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ACON 'nin kısa vadeli varlıkları ( $1.9M ) kısa vadeli yükümlülüklerini ( $1.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: ACON un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ACON şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ACON şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ACON son raporlanan serbest nakit akışına göre 3 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: ACON serbest nakit akışı tahminlerine göre 3 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Aclarion Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Aclarion Provides Update on Non-Compliance with Nasdaq’s Stockholders’ Equity Requirement and Nasdaq’s Bid Price Requirement

Aclarion Receives Non-Compliance Letter from Nasdaq Due to Non-Compliance with the Nasdaq Minimum Stockholders’ Equity Requirement

Aclarion Receives Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Nasdaq Staff Determines to Delist the Aclarion Common Stock from Nasdaq, Unless the Company Timely Requests an Appeal of the Staff’s Determination to A Hearings Panel

Nasdaq Confirms Aclarion Regains Compliance with Rule 5250(c)(1) Regarding Filing of 10-Q Report

Aclarion Announces Update on Non-Compliance Notice from Nasdaq Regarding Late Filing of 10-Q Report

Recent updates

Aclarion Provides Update on Non-Compliance with Nasdaq’s Stockholders’ Equity Requirement and Nasdaq’s Bid Price Requirement

Aclarion, Inc. announced that it has received $1 million in funding

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Aclarion, Inc. has filed a Follow-on Equity Offering in the amount of $1.075 million.

Aclarion Launches Surgeon Partnership to Apply Nociscan's Ai Technology to Personal Injury and Workers Compensation Market

Aclarion Receives Non-Compliance Letter from Nasdaq Due to Non-Compliance with the Nasdaq Minimum Stockholders’ Equity Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.44 loss per share (vs US$2.39 loss in 1Q 2023)

Aclarion Receives Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Aclarion, Inc. has completed a Composite Units Offering in the amount of $3.0015 million.

Full year 2023 earnings released: US$8.82 loss per share (vs US$19.61 loss in FY 2022)

Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution

New major risk - Shareholder dilution

Aclarion, Inc. announced that it has received $0.25 million in funding

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.21 loss in 3Q 2022)

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Nasdaq Staff Determines to Delist the Aclarion Common Stock from Nasdaq, Unless the Company Timely Requests an Appeal of the Staff’s Determination to A Hearings Panel

Nasdaq Confirms Aclarion Regains Compliance with Rule 5250(c)(1) Regarding Filing of 10-Q Report

Aclarion Announces Update on Non-Compliance Notice from Nasdaq Regarding Late Filing of 10-Q Report

High number of new and inexperienced directors

Aclarion Receives Non-Compliance Notice From Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aclarion, Inc. Receives Nasdaq Notice Regarding Late Filing of 10-Q Report

Aclarion, Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.25 loss per share (vs US$6.58 loss in FY 2021)

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc. Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Aclarion, Inc.'s Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings released: US$1.35 loss per share (vs US$0.81 loss in 1Q 2021)

Director recently bought US$150k worth of stock